Story Highlight
– Alzheimer’s can cause hallucinations and delusions in patients.
– Limited treatment options for these symptoms in the UK.
– Clinical trial targets hallucinations with investigational medicine.
– Participants receive close monitoring and health assessments.
– Eligibility includes Alzheimer’s diagnosis and stable medication use.
Full Story
Alzheimer’s Disease is often associated primarily with memory loss, yet there is a less commonly understood aspect affecting many individuals: the presence of hallucinations and delusions. These symptoms can include seeing or hearing things that are not there, misidentifying loved ones, or developing unfounded beliefs, such as the presence of intruders at home. For patients living with Alzheimer’s and their families, these experiences can lead to significant distress and emotional turmoil.
In the UK, options for treating these symptoms remain limited. Although some antipsychotic medications may be prescribed in cases of severe distress, their use is generally met with caution due to potential side effects, underscoring the urgent necessity for new and effective treatment alternatives.
To address this need, MAC Clinical Research, located in Greater Manchester, is spearheading a clinical trial investigating a novel oral medication specifically designed to alleviate hallucinations and delusions in Alzheimer’s patients. Prior to this phase, the medicine underwent safety and tolerability tests in healthy older adults. This next stage aims to evaluate both the safety and how well the medication is processed within the body of patients suffering from Alzheimer’s.
The trial is being conducted at select sites across the UK and is primarily targeting individuals in the early to mid-stages of Alzheimer’s. While participation in clinical trials carries no assurance of direct medical benefit, volunteers will receive comprehensive monitoring from qualified healthcare professionals along with routine health assessments. Their involvement not only aids in personal health management but also contributes to vital research that could enhance the understanding of Alzheimer’s and future treatment possibilities.
Dr Giuseppe Fiore, the principal investigator and senior research physician at MAC Clinical Research, remarked on the impact of these symptoms: “These symptoms are incredibly hard to live with, both for the person experiencing them and for the people who love them. This study is a genuine attempt to find something that helps.” Dr Fiore is actively encouraging families from Greater Manchester who care for individuals diagnosed with Alzheimer’s to consider their eligibility for the study.
According to NHS England statistics, over half a million individuals had received a formal diagnosis of Alzheimer’s as of April 2025, while the actual number may be much larger when accounting for those who remain undiagnosed. Predictions indicate the dementia population in the UK could rise to around 1.4 million by 2040, signalling a growing public health challenge.
MAC Clinical Research, founded in 1988, has established itself as a reputable clinical research organisation with a particular focus on central nervous system disorders, including Alzheimer’s. Their facilities in Greater Manchester are designed not only for research but also provide a comfortable environment that prioritises privacy and accessibility for participants. The organisation adheres to a patient-first ethos, emphasising clear communication, safety, and empathetic support, ensuring that participants and their families feel informed and secure throughout the trial process.
Dr Fiore highlighted the positive feedback from participants who have described the supportive environment of the research team. “Participants consistently highlight the supportive and professional nature of our teams. They value clear communication, compassionate care, and the time we take to explain every step of the trial process. Many also appreciate the reassurance of regular health monitoring and the opportunity to play an active role in advancing medical research.”
Involvement in the clinical trial entails a series of visits to the Greater Manchester clinic, starting with a screening appointment to assess eligibility. This initial assessment leads to a residential stay lasting approximately three nights at the clinic, followed by up to twelve outpatient visits spread across eight weeks. Although participants may not receive immediate medical benefits, they will be engaged in close medical supervision, cognitive evaluations, and health checks, all provided at no cost.
Moreover, the involvement of a study partner, such as a family member or caregiver, is critical for the trial. This person will provide additional support, help document daily changes, and ensure consistent attendance at clinic visits. Reasonable travel expenses will be reimbursed or transport arrangements will be made to facilitate attending the clinic.
Participation is entirely voluntary, and individuals can withdraw from the study at any point for any reason. It is important to note that involvement in the trial will not affect the standard NHS care that participants receive. For many families facing the challenges of Alzheimer’s, the decision to engage in research may represent a proactive and optimistic step in navigating their circumstances.
Acknowledging the investment of time and effort required, MAC Clinical Research offers compensation to both participants and their caregivers or study partners, potentially accumulating up to £1,595 based on the number of completed visits.
Eligibility for the trial is determined following a comprehensive clinical evaluation, with typical criteria including individuals aged between 50 and 85 who have a confirmed diagnosis of Alzheimer’s Disease. Participants should also have daily contact with a caregiver capable of attending all clinic visits, along with maintaining a stable dose of certain Alzheimer’s medications.
Those interested in exploring eligibility, or family members seeking further information, are encouraged to reach out for an initial discussion with the research team. The team is committed to explaining the study clearly, addressing any queries, and assisting in determining the suitability of participation without any pressure to proceed. Collaborating GPs will be kept informed throughout the process to ensure comprehensive care continuity.
For more details, interested persons can visit researchforyou.co.uk or use the freephone number 0800 917 7679. This trial is subject to oversight by an independent UK Research Ethics Committee, with approval from the MHRA, ensuring ethical compliance and the safety of participants throughout the study.
In summary, as the number of individuals living with Alzheimer’s continues to increase, innovative approaches to treatment research like those conducted by MAC Clinical Research are crucial. Their ongoing efforts represent a significant step towards understanding and potentially mitigating some of the more distressing symptoms associated with this challenging condition.
Our Thoughts
The article discusses the ongoing clinical trial for a new investigational medicine targeting hallucinations and delusions in Alzheimer’s patients. While the trial emphasizes patient safety and rigorous monitoring, several aspects highlight areas for improved safety practices.
Firstly, greater emphasis on informed consent and ensuring participants fully understand risks and benefits could enhance compliance with the Health and Safety at Work Act 1974, which mandates the safeguarding of health and safety for patients in clinical settings. Moreover, the importance of a comprehensive risk assessment should be reiterated, particularly regarding the potential side effects of using antipsychotic medicines in vulnerable populations.
The Medicines for Human Use (Clinical Trials) Regulations 2004 require robust protocols to protect participants in trials, including adequate oversight and emergency procedures, which should be rigorously enforced to mitigate any adverse events.
To prevent similar incidents, it would be beneficial for clinical trial organizations to implement enhanced training for staff on recognizing and managing psychiatric symptoms, thus improving overall participant care and safety. Additionally, a more structured feedback mechanism from participants and caregivers could provide vital insights to further refine safety measures throughout the trial process.
